GSE224105 GSE224108 zearalenone 3 v 2 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE224105_GSE224108_zearalenone_3_v_2_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE224105_GSE224108_zearalenone_3_v_2_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE224105_GSE224108_zearalenone_3_v_2_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE224105_GSE224108_zearalenone_3_v_2_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

tripartite motif containing 16 like (pseudogene)

Gene

CASTOR family member 3, pseudogene

Gene

MIR1915 host gene

Gene

TGF-beta induced TARBP2 interacting lncRNA

Gene

long intergenic non-protein coding RNA 1133

Gene

LBX2 antisense RNA 1

Gene

C2orf74 divergent transcript

Gene

long intergenic non-protein coding RNA 2677

Gene

UNC5B antisense RNA 1

Gene

SNX10 antisense RNA 1

  • Gene

    tripartite motif containing 16 like (pseudogene)


  • Gene

    CASTOR family member 3, pseudogene



  • Gene

    TGF-beta induced TARBP2 interacting lncRNA


  • Gene

    long intergenic non-protein coding RNA 1133


  • Gene

    LBX2 antisense RNA 1


  • Gene

    C2orf74 divergent transcript


  • Gene

    long intergenic non-protein coding RNA 2677


  • Gene

    UNC5B antisense RNA 1


  • Gene

    SNX10 antisense RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.